Patents Examined by Daniel R Carcanague
  • ALK5 inhibitors
    Patent number: 11730720
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: August 22, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Svitlana Kulyk, Christina Owens, Steven D. E. Sullivan, Jennifer Kozak, Adam D. Hughes
  • Synthesis of intermediates for the preparation of alpha-tocopherol
    Patent number: 11724996
    Abstract: The present invention relates to a novel synthetic pathway for alpha-tocopherol. The invention discloses different reactions yielding some new intermediates in a very high yield and stereoselectivity.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: August 15, 2023
    Assignee: DSM IP ASSETS B.V.
    Inventors: Ulla Letinois, Thomas Netscher, August Ruettimann
  • Therapeutic dendrimers
    Patent number: 11717574
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: August 8, 2023
    Assignee: ASTRAZENECA AB
    Inventors: Marianne Bernice Ashford, Iain Grant, Edward John Hennessy, William Mccoull, Michael Giannis, Brian Kelly, David Owen, John Paul Secrist
  • Bis-cyclic guanidines as antibacterial agents
    Patent number: 11718585
    Abstract: Provided are novel bis-cyclic guanidine compounds, and the use thereof for treating bacterial infection.
    Type: Grant
    Filed: November 1, 2021
    Date of Patent: August 8, 2023
    Assignee: University of South Florida
    Inventors: Jianfeng Cai, Peng Teng, Alekhya Nimmagadda
  • Compound, epoxy curing catalyst and method for producing compound
    Patent number: 11718587
    Abstract: A novel compound suitable as an epoxy curing catalyst; an epoxy curing catalyst using the compound; and a method for producing the compound. A compound represented by formula (1) in which Xm+ represents an m valent counter cation, R1 represents an aromatic group which may have a substituent; R2 represents an alkylene group which may have a substituent; R3 represents a halogen atom, a hydroxyl group, a mercapto group, a sulfide group, a silyl group, a silanol group, a nitro group, a nitroso group, a sulfonic acid ester group, a phosphino group, a phosphinyl group, a phosphonic acid ester group or an organic group; m represents an integer of 1 or more; n represents an integer of 0-3; and R2 may bond with R1 to form a cyclic structure.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: August 8, 2023
    Assignees: Tokyo Ohka Kogyo Co., Ltd., Daicel Corporation
    Inventors: Kunihiro Noda, Hiroki Chisaka, Issei Suzuki, Jiro Hikida, Dai Shiota, Kieko Hanano, Kyohei Ishida, Tsutomu Watanabe, Kazuhiro Uehara
  • 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
    Patent number: 11713308
    Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: August 1, 2023
    Assignee: YUHAN CORPORATION
    Inventors: Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Eui Chul Lee, Sol Park, Hyok Jun Cho, Cheol Hee Lim, So Young Kim, Hyun Ho Choi, Da Na Jeong, Na Yeon Yang, Na Ry Ha
  • Bicyclic compounds as kinase modulators, methods and uses thereof
    Patent number: 11702425
    Abstract: The present disclosure relates to derivatives of bicyclic compounds and their uses in therapy. In particular, the present disclosure relates to derivatives of bicyclic compounds for use in modulating kinase enzymatic activity and accordingly modulating kinase-dependent diseases and conditions such as cancer and in specific embodiments, hepatocellular carcinoma (HCC). The present disclosure also relates to methods of synthesizing these compounds.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: July 18, 2023
    Assignee: Agency for Science, Technology and Research
    Inventor: Vikrant Arun Adsool
  • Chemical compounds
    Patent number: 11702405
    Abstract: The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: July 18, 2023
    Assignee: Pfizer Inc.
    Inventors: Ariamala Gopalsamy, Shawn Cabral, Agustin Casimiro-Garcia, Ming Zhu Chen, Chulho Choi, Robert Lee Dow, Olugbeminiyi Omezia Fadeyi, David Hepworth, Jayasankar Jasti, Lyn Howard Jones, Arjun Venkat Narayanan, Mihir Dineshkumar Parikh, David Walter Piotrowski, Lee Richard Roberts, Ralph Pelton Robinson, Jr., Hatice Gizem Yayla
  • Charged ion channel blockers and methods for use
    Patent number: 11696912
    Abstract: The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: July 11, 2023
    Assignee: Nocion Therapeutics, Inc.
    Inventors: Bridget McCarthy Cole, James Lamond Ellis
  • Personal care compositions
    Patent number: 11690833
    Abstract: Described herein are complexes comprising a cationic antibacterial agent and a metal salt, personal care compositions comprising same; along with methods of making and using these complexes and compositions.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: July 4, 2023
    Assignee: Colgate-Palmolive Company
    Inventors: Viktor Dubovoy, Junhong Mao, Ravi Subramanyam, Long Pan, Tatiana Brinzari
  • Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
    Patent number: 11690847
    Abstract: A method of treating intestinal gastrointestinal, or bowel disorders in a subject in need thereof includes administering to the subject a therapeutically effective amount of 15-PGDH inhibitor alone or in combination with a corticosteroid and/or TNF alpha antagonist.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: July 4, 2023
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Sanford Markowitz, Won Jin Ho, Stephen P. Fink, Vinay Varadan
  • Inhibitors of receptor interacting protein kinase I for the treatment of disease
    Patent number: 11690850
    Abstract: Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: July 4, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard T. Lewis, Matthew Hamilton, William J. Ray, Fernando Alvarez, Naphtali Reyna, Jason Cross, Suyambu Kesava Vijayan Ramaswamy
  • Preparation and composition for treatment of malignant tumors
    Patent number: 11690843
    Abstract: It is intended to provide a novel method for treating a cancer using an FGFR inhibitor that exhibits a remarkably excellent antitumor effect and has fewer side effects. The present invention provides a combination preparation for the treatment of a malignant tumor comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, and one or more additional compound(s) having an antitumor effect or pharmaceutically acceptable salt(s) thereof, and a pharmaceutical composition comprising both the active ingredients. The present invention also provides an antitumor effect enhancer, an antitumor agent, a kit for malignant tumor treatment, etc. comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: July 4, 2023
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Akihiro Miura, Hiroshi Sootome
  • YAP1 inhibitors that target the interaction of YAP1 with OCT4
    Patent number: 11685725
    Abstract: Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2, which is a transcription actor necessary for the self-renewal of stem-like cells from non-small cell lung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WW domain could prevent the induction of Sox2 and sternness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit sternness. Disclosed are compounds that affect the Yap1:Oct4 interaction.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: June 27, 2023
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Srikumar Chellappan, Nicholas J. Lawrence, Sujeewa Ranatunga Mahanthe Mudiyanselage
  • CDK inhibitors and their use as pharmaceuticals
    Patent number: 11673893
    Abstract: The disclosure is directed to, in part, to CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: June 13, 2023
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Liang Lu, Rupa Shetty, Andrew Paul Combs, Chaofeng Dai, Raul Andrew Leal, Klare Lazor Bersch
  • Process for the preparation of highly pure Salcaprozic Acid and pharmaceutically acceptable salts thereof
    Patent number: 11667614
    Abstract: Processes that use novel reagents for the removal of colored impurity during the preparation of Salcaprozic Acid and pharmaceutically acceptable salts thereof. The processes include hydrolysis of 8-(2,4-dioxo-1,3-benzoxazin-3-yl)octanoic acid ethyl ester in the presence of or by contacting it with benzotriazole, hydrazine and/or sodium borohydride.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: June 6, 2023
    Assignee: Navinta III Inc.
    Inventors: Pankaj Vasudev Parmar, Raja Jeyakumar John Muthiah, Vikas Kantilal Chauhan, Jagdish Kanjibhai Solanki
  • Process for preparing a compound useful to treat mycoses
    Patent number: 11661415
    Abstract: A process for preparing a compound of formula (II): includes reacting a compound of formula (VIII): with a compound of formula (XIV):
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: May 30, 2023
    Assignee: PULMOCIDE LIMITED
    Inventors: Thomas Christopher Colley, Kazuhiro Ito, Garth Rapeport, Peter Strong, Peter John Murray, Stuart Thomas Onions, Mihiro Sunose
  • Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders
    Patent number: 11661404
    Abstract: AKR1C3-activated prodrugs of Formula (I), pharmaceutical compositions comprising prodrugs of Formula (I), and their use in the treatment of hyperproliferative diseases such as cancer and for cell ablation. The compounds of the invention are able to penetrate neoplasm tissue and be selectively reduced to an active (cytotoxic) form by contact with an AKR1C3 enzyme found in the neoplasm. This active form is therefore able to ablate AKR1C3-expressing target cells of the neoplasm and therefore has particular utility in the treatment of cancer and other hyperproliferative disorders.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: May 30, 2023
    Assignee: ACHILLES MEDICAL LIMITED
    Inventors: Amir Ashoorzadeh, Christopher Paul Guise, Adam Vorn Patterson, Jeffrey Bruce Smaill
  • MASP-2 inhibitors and methods of use
    Patent number: 11661418
    Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: May 30, 2023
    Assignee: OMEROS CORPORATION
    Inventors: Neil S. Cutshall, Jennifer Lynn Gage, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Thomas L. Little, Markus Metz, Peter Kurt Nollert Von Specht, Loren Michael Price, Jennifer Tsoung
  • Aminothiazole compounds as inhibitors of CTPS1
    Patent number: 11655246
    Abstract: Compounds of formula (I): (I) and related aspects.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 23, 2023
    Assignee: STEP PHARMA S.A.S.
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Elli Chatzopoulou, Emma Blackham, Geraint Jones, Jennifer Thomas, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed